Laquinimod for MS misses primary endpoint in BRAVO trial

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Laquinimod for MS misses primary endpoint in BRAVO trial

Postby MSUK » Mon Aug 01, 2011 5:30 am

Image

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today initial results from the Phase III BRAVO study, which was designed to evaluate the efficacy, safety and tolerability of oral laquinimod compared to placebo and to provide a benefit-risk assessment comparing oral laquinimod BRAVO is the second of two pivotal Phase III studies in the clinical development program for laquinimod, an investigational, oral, once-daily therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS). Results showed that the BRAVO study did not achieve its primary endpoint of reducing the annualized relapse rate (p=0.075).... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1735
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2211
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Re: Laquinimod for MS misses primary endpoint in BRAVO trial

Postby HarryZ » Mon Aug 01, 2011 6:03 am

Averaging out the numbers after the Teva two-step in explaining the results, they seem to be hovering around the same approx 33% efficacy numbers we have seen in the past.

Not too promising in the very competitive world of MS drugs.

Harry
User avatar
HarryZ
Family Elder
 
Posts: 2557
Joined: Tue May 25, 2004 2:00 pm
Location: London, ON, Canada


Return to General Discussion

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service